Heartflow

Heartflow EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Heartflow (HTFL) as of Nov 12, 2026 is -64.07 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -73.61 M USD — a change of -12.96% (higher).

EBITDA

-64.07 MUSD

YoY

-12.96%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Heartflow is 2025 -64.07 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Heartflow was 2024 -73.61 M USD. It decreases by -12.96% higher compared to the previous year.

The Heartflow EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2023
-75.87 M USD
Jan 1, 2024
-73.61 M USD
Jan 1, 2025
-64.07 M USD
The Heartflow EBITDA history
YEAREBITDAYoY
-64.07 MUSD-12.96%
-73.61 MUSD-2.99%
-75.87 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartflow Stock analysis

What does Heartflow do? Heartflow Inc generates revenue through its HeartFlow Platform, which includes AI-driven software solutions for diagnosing coronary artery disease. The company's products, such as HeartFlow FFRCT Analysis and Plaque Analysis, assist physicians in managing patient care by providing personalized 3D heart models derived from CCTA scans. These tools are sold to healthcare providers and hospitals, enabling non-invasive diagnosis and treatment planning for coronary artery disease. The RoadMap Analysis offers intuitive visualization of coronary arteries, helping physicians focus on critical areas during patient reviews. The HeartFlow Platform leverages artificial intelligence and computational fluid dynamics to create detailed cardiac models, positioning Heartflow Inc as a leader in medical technology for cardiovascular diagnostics. Its commercial-stage operations focus on delivering precision care solutions that improve diagnostic accuracy and patient outcomes. Healthcare institutions purchase these AI-powered tools to enhance their diagnostic capabilities without invasive procedures. Heartflow is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Heartflow stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Heartflow is -64.07 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Heartflow changed from -73.61 M USD to -64.07 M USD, representing a -12.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Heartflow since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Heartflow historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Heartflow

All Key Metrics — Heartflow